ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Timolol

Also written as “Timolol Maleate Gel”, “bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)” and “timolol 0.5%”.

Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Hemangioma, Capillary, led by 9 companies.

Drug pageTimolol: every studyMany companies study it; this page follows only the 23 they lead. All 84 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 13, 200823 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVieits history only80 open or runningphase 4since Aug 13, 2008Aug 13, 2008none ahead
Merckits history only30 open or runningphase 3since Apr 12, 2005Apr 12, 2005none ahead
Santen Pharmaceutical30 open or runningphase 3since Feb 28, 2011Apr 7, 2009none ahead
Viatrisits history only30 open or runningphase 3since Sep 8, 2005Sep 8, 2005none ahead
Auson Pharmaceuticalsits history only20 open or runningphase 3since Oct 29, 2024Oct 29, 2024none ahead
Credit Valley EyeCareits history only10 open or runningphase 4since Feb 13, 2012Feb 13, 2012none ahead
Glaukosits history only10 open or runningphase 4since Jun 1, 2009Jun 1, 2009none ahead
Laboratorios Poenits history only10 open or runningphase 4since Mar 30, 2023Mar 30, 2023none ahead
Vistakon Pharmaceuticalsits history only10 open or runningphase 4since Dec 5, 2008Dec 5, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Santen Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 7, 2009First study: phase 1 study in HealthyFirst studyNCT00879099 · 12 enrolled · Finland
  2. Feb 28, 2011Phase 3 study in Ocular HypertensionNCT01306461 · 401 enrolled · Hungary
  3. Sep 12, 2011Phase 1 study in Healthy VolunteersNCT01434888 · 15 enrolled · Finland

TargetBeta

ADRB1 →ADRB2 →read by rule
“Beta-1 adrenergic receptor antagonist; Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Epinephrinerulenasus-pharmaphase 417

Studies

All 3 Santen Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01434888Healthy Volunteers · Finland1CompletedDec 201115
NCT01306461Ocular Hypertension · Hungary3CompletedApr 2012401
NCT00879099Healthy · Finland1CompletedJan 201012

How it is read

Names in the registry

  • “Timolol Maleate Gel”, 4 entries
  • “Timolol”, 3 entries
  • “bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)”, 2 entries
  • “timolol 0.5%”, 2 entries
  • “timolol maleate”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.